In 1958, the term Gastroparesis diabeticorum was coined by Kassender to describe asymptomatic gastric retention in diabetic patients [1]
The GLP-1s that were originally marketed as a diabetes treatment include semaglutide, brand name Ozempic, liraglutide, brand name Victoza, dulaglutide, brand name Trulicity, and the latest GLP-1 to the market, tirzepitide, brand name Mounjaro, which is a combination GIP/GLP-1
The drug had to be injected twice a day, which had to be done within 15-30 minutes before breakfast and dinner
Cost of Oral vs Injectable and Other Therapies No new drug adoption is possible without the proper cost-related analysis in relation to already available options
Cardiometabolic parameters during GLP-1 RA treatment GLP-1 RAs have also demonstrated important cardioprotective benefits that extend beyond their impact on BW loss
For weight loss, data from a 2021 review supports semaglutide as the most effective option